PLAY PODCASTS
BioSpace

BioSpace

BioSpace

259 episodesEN

Show overview

BioSpace has been publishing since 2023, and across the 3 years since has built a catalogue of 259 episodes. That works out to roughly 85 hours of audio in total. Releases follow a several-times-a-week cadence.

Episodes typically run ten to twenty minutes — most land between 16 min and 23 min — though episode length varies meaningfully from one episode to the next. None of the episodes are flagged explicit by the publisher. It is catalogued as a EN-language Science show.

The show is actively publishing — the most recent episode landed 3 days ago, with 71 episodes already out so far this year. The busiest year was 2025, with 92 episodes published.

Episodes
259
Running
2023–2026 · 3y
Median length
19 min
Cadence
Several per week

From the publisher

Unravel the business of science with BioSpace. We dive into biopharma's top stories and biggest challenges, whether it’s layoffs, pipeline shake-ups, acquisitions, new FDA approvals or how to regulate AI in drug development.

Latest Episodes

View all 259 episodes

Rewriting the rules of CMV prevention

Aug 20, 202619 min

Amylyx’s redemption story, Summit’s survival woes, Definium’s anxiety win, more

Aug 19, 202619 min

The Italian inflection point: Clinical strength, culture and capital

Aug 13, 202618 min

Replimune finally wins approval, Q2 earnings wrap up, psychedelics stay in spotlight

Aug 12, 202619 min

Rumors of biggest pharma merger ever drop amid Q2 earnings, contentious FDA adcomms

Aug 11, 202623 min

The next treatment-resistant depression paradigm

Aug 6, 202620 min

Rumors of biggest pharma merger ever drop amid Q2 earnings, contentious FDA adcomms

Aug 5, 202624 min

Life after the lead asset: Advancing an early-stage pipeline

Jul 30, 202624 min

Capricor and Replimune prep for FDA adcomms, Q2 earnings roll on, Sarepta’s new leader, more

Jul 29, 202617 min

Nordic biotech’s next act: From fragmentation to global force

Jul 23, 202620 min

Q2 earnings underway, FDA’s CRL kerfuffle, IPOs full speed ahead in H2

Jul 22, 202621 min

The future of pain relief: Exploring opioid alternatives

Jul 16, 202619 min

Biogen validates anti-tau approach at AAIC, psychedelics full speed ahead, ATTR-CM shakeup

Jul 15, 202621 min

Bonus: Q2 2026 Job Market Update

Jul 14, 20269 min

From sequence to scale: Gene editing’s new era in biologics manufacturing

Jul 10, 202620 min

Vertex carries M&A uptick into H2, IPOs and VC raises also grow, FDA on pace despite turmoil

Jul 8, 202617 min

Sentiment at BIO soars as FDA resets, dealmaking evolves; Amgen’s Tavneos in hot water

Jul 1, 202622 min

The Golden Triangle and the gaps: Rethinking UK biotech

Jun 25, 202619 min

AbbVie keeps M&A rolling, FDA’s reversal train chugs along, BIO 2026 dispatch, more

Jun 24, 202621 min

From fragile skin to living medicine: Lessons from RDEB

Jun 18, 202621 min
2026 BioSpace